CX-904 is a conditionally activated T-cell-engaging bispecific designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells within the tumor microenvironment. CX-904 uses CytomX’s Probody peptide-masking technology to reduce binding to EGFR and CD3 in normal tissues and direct binding towards tumor tissue.
Purpose: The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of CX-904 in adult subjects with metastatic or locally advanced unresectable solid tumors.
If you are interested in learning more about this study including participating sites, please visit clinicaltrials.gov.
BMS-986288 is a next-generation anti-CTLA-4 non-fucosylated Probody therapeutic, designed to be conditionally activated in the tumor microenvironment with enhanced CD16 binding and increased APC-mediated T-cell priming capabilities
Bristol Myers Squibb is enrolling patients in a Phase 1/2 clinical trial (NCT03994601) evaluating BMS-986288 alone or in combination with Opdivo® (nivolumab) in patients with selected advanced solid cancers.
Purpose: The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.
If you are interested in learning more about this study including participating sites, please visit clinicaltrials.gov.